

**Medical Membranes Market by Material (PSU, PES, PVDF, PTFE, PP, PAN, PA, Modified Acrylics), Process Technology (Ultrafiltration, Microfiltration, Nanofiltration), Application (Pharmaceutical Filtration, Hemodialysis, IV Fusion & Sterile Filtration, Membrane Oxygenator), and Region - Global Forecast to 2030**

Market Report | 2025-11-28 | 241 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The medical membranes market is projected to reach USD 6.66 billion by 2030 from USD 4.31 billion in 2025, at a CAGR of 9.1% during the forecast period. The global medical membranes market is driven by the increasing number of chronic kidney disease and diabetes patients. Continuous innovations in membrane technology like better biocompatibility, antifouling coatings, and nanofiltration capabilities are making drug purification, bioprocessing, and artificial organ applications possible. Additionally, the increasing number of surgical procedures, preference for advanced wound dressings, and tissue engineering scaffolds are also supporting market growth. Meanwhile, there is strong investment in single-use disposable membrane systems in biotech and pharmaceutical manufacturing for eliminating cross-contamination. Moreover, the healthcare infrastructure in emerging markets (especially Asia Pacific), the aging population in mature regions, and significant R&D on bio-artificial organs and regenerative medicine are all contributing to the market growth.

<https://mnmimg.marketsandmarkets.com/Images/medical-membrane-advanced-technologies-and-global-market-img-overview.webp>

"Polyvinylidene fluoride (PVDF) is the fastest-growing material segment in the medical membranes market during the forecast period."

Polyvinylidene fluoride (PVDF) is the fastest-growing segment in the medical membranes market due to its excellent properties. PVDF is known for its chemical resistance, heat stability, physical strength, and low protein adherence and, thus, is widely used in

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

the purification of liquids in pharmaceuticals and biopharmaceuticals, alongside blood filtering, drug purification, and filtration of the final products of biopharmaceuticals. Hydrophilic PVDF membranes are increasingly used in medical diagnostics and biologics production, driven by the worldwide rise in chronic diseases, the growing focus on personalized medicine, and the expanding aging population. PVDF's biocompatibility is a key factor for innovations in tissue engineering, wound dressings, and virus removal, which makes it superior to competitors such as PTFE or PESU. At the same time, the pandemic-induced surge in pharmaceutical manufacturing and increased investments in advanced filtration technologies also favor PVDF.

"Ultrafiltration is projected to be the largest process technology segment in the medical membranes market during the forecast period."

Ultrafiltration (UF) is the largest technology segment in the overall medical membranes market due to its essential application in hemodialysis. Hemodialysis overcomes the limits of kidney function in more than 3 million end-stage renal disease patients, curing them by highly efficient removal of ureotoxins and keeping essential proteins in the body. UF membranes are often made from polysulfone, polyethersulfone, or modified PES, and they have precise corresponding molecular weight cut-offs (5-50kDa) that give excellent biocompatibility as well as high flux rates and superior hemocompatibility. Thus, they have become the standard for purification in dialysis clinics and ICUs. The strong growth of the medical membranes market is also supported by the expanding use of ultrafiltration (UF) beyond renal therapy. UF is widely applied in microbiology and pharmaceutical downstream processing for concentrating, diafiltering, and exchanging buffers in monoclonal antibodies, vaccines, and recombinant proteins, all of which are increasing rapidly with the rise of biologics. Its ability to pump at low transmembrane pressure and usage of advanced surface modifications to reduce fouling make it even more preferred over microfiltration, reverse osmosis, or nanofiltration in high-volume, high-value medical applications.

"Europe is projected to be the second-largest medical membranes market during the forecast period."

Europe is the second-largest medical membranes market. The market in the region is driven by its excellent healthcare systems, high spending on renal care per capita, and a large number of elderly people with a high prevalence of chronic kidney diseases. The market in the region is also supported by the presence of major membrane manufacturers with significant R&D and production capacity in Germany, France, Italy, and Switzerland. Stringent EU regulatory standards ensure that only the best products are delivered to the market. However, this creates barriers for new players. Moreover, widespread reimbursement for dialysis treatments, the growing use of single-use bioprocessing systems in the fast-expanding biologics sector, and significant public and private investments in fields like regenerative medicine and bioartificial organs contribute to the demand for the product.

Extensive primary interviews were conducted to determine and verify the market size for several segments and subsegments and the information gathered through secondary research.

The breakdown of primary interviews is given below:

-□By Department: Tier 1 - 40%, Tier 2 - 25%, and Tier 3 - 35%

-□By Designation: C Level - 35%, Director Level - 30%, and Executives - 35%

-□By Region: North America - 25%, Europe - 45%, Asia Pacific - 20%, South America - 5%, and Middle East & Africa - 5%

Asahi Kasei Corporation (Japan), Mann+Hummel (Germany), Sartorius AG (Germany), Merck KGaA (Germany), Solventum (US), Cytiva (US), W. L. Gore & Associates, Inc. (US), Kovalus Separation Solutions (US), and Cobetter (China), among others, are some of the key players in the medical membranes market. The study includes an in-depth competitive analysis of these key players in the medical membranes market, with their company profiles, recent developments, and key market strategies.

#### Research Coverage

The market study covers the medical membranes market across various segments. It aims to estimate the market size and the growth potential of this market across different segments based on material, process technology, application, and region. The study also includes an in-depth competitive analysis of key players in the market, their company profiles, key observations related to their products and business offerings, recent developments undertaken by them, and key growth strategies adopted by them to improve their position in the medical membranes market.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Key Benefits of Buying the Report

The report is expected to help the market leaders/new entrants in this market with the closest approximations of the revenue numbers of the overall medical membranes market and its segments and subsegments. This report is projected to help stakeholders understand the competitive landscape of the market, gain insights to improve the position of their businesses, and plan suitable go-to-market strategies. The report also aims to help stakeholders understand the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

- Analysis of key drivers (Rising prevalence of chronic diseases, Growing adoption of membrane-based separation technologies, Increasing number of surgical procedures), restraints (High cost of advanced medical membranes, Stringent regulatory approval processes, Risk of membrane fouling and limited lifespan of membranes), opportunities (Growing demand for single-use membrane systems in bioprocessing, Expansion in emerging markets, Integration of nanotechnology and smart membranes), challenges (Complexity in scaling up production of high-performance membranes, Environmental concerns, and Intense competition).
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the medical membranes market
- Market Development: Comprehensive information about lucrative markets - the report analyses the medical membranes market across varied regions.
  - Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the medical membranes market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Asahi Kasei Corporation (Japan), Mann+Hummel (Germany), Sartorius AG (Germany), Merck KGaA (Germany), Solventum (US), Cytiva (US), W. L. Gore & Associates, Inc. (US), Kovalus Separation Solutions (US), and Cobetter (China), among others

## Table of Contents:

1	INTRODUCTION	23
1.1	STUDY OBJECTIVES	23
1.2	MARKET DEFINITION	23
1.3	STUDY SCOPE	24
1.3.1	MARKETS COVERED AND REGIONAL SCOPE	24
1.3.2	INCLUSIONS AND EXCLUSIONS	25
1.3.3	YEARS CONSIDERED	25
1.3.4	CURRENCY CONSIDERED	25
1.3.5	UNIT CONSIDERED	26
1.4	STAKEHOLDERS	26
2	EXECUTIVE SUMMARY	27
3	PREMIUM INSIGHTS	31
3.1	ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MEDICAL MEMBRANES MARKET	31
3.2	MEDICAL MEMBRANES MARKET, BY APPLICATION	31
3.3	MEDICAL MEMBRANES MARKET, BY MATERIAL	32
3.4	MEDICAL MEMBRANES MARKET, BY PROCESS TECHNOLOGY	32
3.5	MEDICAL MEMBRANES MARKET, BY REGION	33
4	MARKET OVERVIEW	34
4.1	INTRODUCTION	34
4.2	MARKET DYNAMICS	35
4.2.1	DRIVERS	35
4.2.1.1	Rising prevalence of chronic diseases	35
4.2.1.2	Advancements in biotechnology and drug delivery systems	36

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

4.2.1.3	Rising demand for hemodialysis and filtration technologies	36
4.2.1.4	Expansion of healthcare infrastructure and increasing access globally	37
4.2.2	RESTRAINTS	37
4.2.2.1	High manufacturing and production costs	37
4.2.2.2	Stringent regulatory approvals and compliance	38
4.2.2.3	Membrane fouling and degradation issues	38
4.2.3	OPPORTUNITIES	39
4.2.3.1	Growing demand for single-use membrane systems in bioprocessing	39
4.2.3.2	Rapid expansion of medical membranes into emerging economies	39
4.2.4	CHALLENGES	40
4.2.4.1	Complexity in scaling up production of high-performance membranes	40
4.2.4.2	Environmental concerns	40
4.3	UNMET NEEDS AND WHITE SPACES	41
4.3.1	UNMET NEEDS IN MEDICAL MEMBRANES MARKET	41
4.3.2	WHITE SPACE OPPORTUNITIES	41
4.4	INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES	41
4.4.1	INTERCONNECTED MARKETS	41
4.4.2	CROSS-SECTOR OPPORTUNITIES	42
4.5	EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS	42
4.5.1	EMERGING BUSINESS MODELS	42
4.5.2	ECOSYSTEM SHIFTS	42
4.6	STRATEGIC MOVES BY TIER-1/2/3 PLAYERS	42
4.6.1	KEY MOVES AND STRATEGIC FOCUS	43
5	INDUSTRY TRENDS	44
5.1	PORTER'S FIVE FORCES ANALYSIS	44
5.1.1	THREAT OF NEW ENTRANTS	45
5.1.2	THREAT OF SUBSTITUTES	45
5.1.3	BARGAINING POWER OF SUPPLIERS	45
5.1.4	BARGAINING POWER OF BUYERS	46
5.1.5	INTENSITY OF COMPETITIVE RIVALRY	46
5.2	MACROECONOMIC INDICATORS	46
5.2.1	GLOBAL GDP TRENDS	46
5.3	VALUE CHAIN ANALYSIS	48
5.4	ECOSYSTEM ANALYSIS	50
5.5	PRICING ANALYSIS	52
5.5.1	AVERAGE SELLING PRICE TREND, BY REGION	52
5.6	TRADE ANALYSIS	53
5.6.1	IMPORT SCENARIO (HS CODE 901890)	53
5.6.2	EXPORT SCENARIO (HS CODE 901890)	54
5.7	KEY CONFERENCES AND EVENTS	55
5.8	TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS	56
5.9	INVESTMENT AND FUNDING SCENARIO	57
5.10	CASE STUDY ANALYSIS	57
5.10.1	ENSURING RELIABLE CLEANABILITY OF MEDICAL ULTRAFILTRATION MEMBRANES - MERCK MILLIPORE	57
5.10.2	ADVANCED MEDICAL MEMBRANE SOLUTION FOR HOSPITAL WASTEWATER TREATMENT BY IMEMFLO	58
5.11	2025 US TARIFF	58

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.11.1	INTRODUCTION	58
5.11.2	KEY TARIFF RATES	59
5.11.3	PRICE IMPACT ANALYSIS	59
5.11.4	IMPACT ON KEY REGIONS	60
5.11.4.1	North America	60
5.11.4.2	Europe	60
5.11.4.3	Asia Pacific	60
5.11.5	IMPACT ON END-USE INDUSTRIES	61
6	STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS	62
6.1	KEY EMERGING TECHNOLOGIES	62
6.1.1	CELL MEMBRANE-COATED NANOPARTICLES (CNPS)	62
6.1.2	BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITE MEMBRANES	62
6.2	COMPLEMENTARY TECHNOLOGIES	63
6.2.1	SURFACE MODIFICATION & ANTIMICROBIAL/ANTIFOULING COATINGS	63
6.3	TECHNOLOGY/PRODUCT ROADMAP	64
6.3.1	SHORT-TERM (2025-2027)   FOUNDATION & EARLY COMMERCIALIZATION	64
6.3.2	MID-TERM (2027-2030)   EXPANSION & STANDARDIZATION	64
6.3.3	LONG-TERM (2030-2035+)   MASS COMMERCIALIZATION & DISRUPTION	65
6.4	PATENT ANALYSIS	66
6.4.1	INTRODUCTION	66
6.4.2	METHODOLOGY	66
6.4.3	DOCUMENT TYPE	66
6.4.4	INSIGHTS	67
6.4.5	LEGAL STATUS OF PATENTS	68
6.4.6	JURISDICTION ANALYSIS	68
6.4.7	TOP APPLICANTS	69
6.4.8	TOP 10 PATENT OWNERS IN LAST 10 YEARS	69
6.5	FUTURE APPLICATIONS	70
6.5.1	NEXT-GENERATION HEMODIALYSIS & ARTIFICIAL ORGANS	70
6.5.2	ADVANCED WOUND-CARE & TISSUE-ENGINEERING MEMBRANES	71
6.5.3	CONTROLLED DRUG-DELIVERY & IMPLANTABLE THERAPEUTIC MEMBRANES	71
6.5.4	POINT-OF-CARE DIAGNOSTICS & MICROFLUIDIC LAB-ON-CHIP DEVICES	72
6.5.5	WEARABLE HEALTH SENSORS & CONTINUOUS BIOMARKER MONITORING	72
6.6	IMPACT OF AI/GEN AI ON MEDICAL MEMBRANES MARKET	73
6.6.1	TOP USE CASES AND MARKET POTENTIAL	73
6.6.2	BEST PRACTICES IN MEDICAL MEMBRANES PROCESSING	74
6.6.3	CASE STUDIES OF AI IMPLEMENTATION IN MEDICAL MEMBRANES MARKET	74
6.6.4	INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS	75
6.6.5	CLIENTS' READINESS TO ADOPT GENERATIVE AI IN MEDICAL MEMBRANES MARKET	75
6.7	SUCCESS STORIES AND REAL-WORLD APPLICATIONS	75
6.7.1	PALL CORPORATION: HEMODIALYSIS MEMBRANES	76
6.7.2	MERCK KGAA: BIOFUNCTIONAL MEMBRANES	76
6.7.3	BAXTER INTERNATIONAL: EXTRACORPOREAL MEMBRANES	76
7	SUSTAINABILITY AND REGULATORY LANDSCAPE	77
7.1	REGIONAL REGULATIONS AND COMPLIANCE	77
7.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
7.1.2	INDUSTRY STANDARDS	78

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2 SUSTAINABILITY INITIATIVES 79
- 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 80
- 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 81
- 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 82
  - 8.1 DECISION-MAKING PROCESS 82
  - 8.2 KEY STAKEHOLDERS AND BUYING CRITERIA 83
    - 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
    - 8.2.2 BUYING CRITERIA 84
  - 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 86
  - 8.4 UNMET NEEDS IN VARIOUS APPLICATIONS 87
  - 8.5 MARKET PROFITABILITY 87
    - 8.5.1 REVENUE POTENTIAL 87
    - 8.5.2 COST DYNAMICS 88
    - 8.5.3 MARGIN OPPORTUNITIES IN KEY END-USE INDUSTRIES 88
- 9 MEDICAL MEMBRANES MARKET, BY MATERIAL 89
  - 9.1 INTRODUCTION 90
  - 9.2 POLYSULFONE (PSU) & POLYETHERSULFONE (PESU) 91
    - 9.2.1 ADVANCING DIALYSIS AND CLINICAL FILTRATION WITH BIOCOMPATIBLE, HIGH-FLUX MEMBRANE TECHNOLOGIES TO DRIVE MARKET 91
    - 9.2.2 POLYVINYLIDENE FLUORIDE (PVDF) 92
      - 9.2.2.1 EXCELLENT MECHANICAL STRENGTH, THERMAL STABILITY, AND CHEMICAL RESISTANCE TO DRIVE MARKET 92
      - 9.2.2.2 HYDROPHOBIC PVDF MEMBRANE 93
      - 9.2.2.3 HYDROPHOBIC PVDF MEMBRANE 93
    - 9.2.3 POLYTETRAFLUOROETHYLENE (PTFE) 93
      - 9.2.3.1 ADVANCING MEDICAL VENT FILTRATION WITH ULTRA-RESILIENT MEMBRANE MATERIALS TO DRIVE MARKET 93
  - 9.3 POLYPROPYLENE (PP) 94
    - 9.3.1 OPTIMIZING THERMAL STABILITY FOR HIGH-TEMPERATURE USE TO DRIVE MARKET 94
  - 9.4 POLYACRYLONITRILE (PAN) 94
    - 9.4.1 PROVIDES SUPERIOR CHEMICAL RESISTANCE IN AGGRESSIVE DRUG FILTRATION TO DRIVE MARKET 94
  - 9.5 POLYAMIDE (PA) 95
    - 9.5.1 ENABLES HIGH PERMSELECTIVITY IN PHARMACEUTICAL NANOFILTRATION AND DRUG CONCENTRATION TO DRIVE MARKET 95
  - 9.6 MODIFIED ACRYLICS 95
    - 9.6.1 DELIVERS UNMATCHED OPTICAL CLARITY FOR HIGH-SENSITIVITY DIAGNOSTIC DEVICES TO DRIVE MARKET 95
  - 9.7 OTHER MATERIALS 96
- 10 MEDICAL MEMBRANES MARKET, BY PROCESS TECHNOLOGY 97
  - 10.1 INTRODUCTION 98
  - 10.2 ULTRAFILTRATION 99
    - 10.2.1 TRANSFORMING MEDICAL PURIFICATION WORKFLOWS WITH HIGH-PERFORMANCE MEMBRANE SOLUTIONS TO DRIVE MARKET 99
  - 10.3 NANOFILTRATION 100
    - 10.3.1 REMOVES ENDOTOXINS, HORMONE RESIDUES, ANTIBIOTICS, AND OTHER TRACES FROM PROCESS WATER AND MEDICAL SOLUTIONS TO DRIVE MARKET 100
  - 10.4 MICROFILTRATION 100
    - 10.4.1 RISING DEMAND FOR ENERGY-EFFICIENT AIR CONDITIONING SYSTEMS AND RETROFITTING OF OLDER BUILDINGS TO DRIVE MARKET 100
  - 10.5 OTHER PROCESS TECHNOLOGIES 101

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11	MEDICAL MEMBRANES MARKET, BY APPLICATION	102
11.1	INTRODUCTION	103
11.2	PHARMACEUTICAL FILTRATION	104
11.2.1	ENHANCING BIOPHARMACEUTICAL SAFETY WITH HIGH-PERFORMANCE MEMBRANE SOLUTIONS TO DRIVE MARKET	104
11.3	HEMODIALYSIS	105
11.3.1	EMPOWERING RENAL SUPPORT WITH PRECISION FILTRATION TO DRIVE MARKET	105
11.4	DRUG DELIVERY	106
11.4.1	ENHANCING TREATMENT RELIABILITY THROUGH CONTROLLED DIFFUSION TECHNOLOGY TO DRIVE MARKET	106
11.5	IV FUSION & STERILE FILTRATION	106
11.5.1	ADVANCING CLINICAL OUTCOMES THROUGH CUTTING-EDGE FILTRATION AND DELIVERY TO DRIVE MARKET	106
11.6	MEMBRANE OXYGENATOR	107
11.6.1	DRIVING EFFICIENT AND SAFE OXYGEN DELIVERY WITH MEMBRANE INNOVATION TO DRIVE MARKET	107
11.7	APHERESIS MEMBRANE	107
11.7.1	TRANSFORMING BLOOD TREATMENT THROUGH ADVANCED MEMBRANE TECHNOLOGY TO DRIVE MARKET	107
11.8	OTHER APPLICATIONS	108
	?	
12	MEDICAL MEMBRANES MARKET, BY REGION	109
12.1	INTRODUCTION	110
12.2	ASIA PACIFIC	111
12.2.1	CHINA	115
12.2.1.1	Accelerating expansion in healthcare filtration technologies to drive market	115
12.2.2	INDIA	116
12.2.2.1	Seizing opportunities in cost-effective dialysis and filtration to drive market	116
12.2.3	JAPAN	117
12.2.3.1	Strengthening healthcare outcomes with high-tech filtration to drive market	117
12.2.4	SOUTH KOREA	118
12.2.4.1	Rising demand from healthcare, pharmaceutical, and biotechnology sector to drive market	118
12.2.5	REST OF ASIA PACIFIC	119
12.3	NORTH AMERICA	121
12.3.1	US	124
12.3.1.1	Surge in construction activities to drive market	124
12.3.2	CANADA	125
12.3.2.1	Rise of new housing projects to drive market	125
12.3.3	MEXICO	127
12.3.3.1	Expanding industrial capabilities and healthcare systems to drive market	127
12.4	EUROPE	128
12.4.1	GERMANY	132
12.4.1.1	Surge in construction of residential infrastructure to drive market	132
12.4.2	UK	133
12.4.2.1	Rising demand for hemodialysis, pharmaceutical filtration, and IV infusion systems to drive market	133
12.4.3	FRANCE	134
12.4.3.1	Policy and financial incentives for building renovation and low-carbon heating to drive market	134
12.4.4	ITALY	136
12.4.4.1	Investments in residential buildings and renovation activities to drive market	136
12.4.5	SPAIN	137
12.4.5.1	High demand for commercial air conditioning units to drive market	137
12.4.6	REST OF EUROPE	138

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.5 MIDDLE EAST & AFRICA 139
  - 12.5.1 SAUDI ARABIA 142
    - 12.5.1.1 Trend of small and affordable housing units to drive market 142
  - 12.5.2 UAE 143
    - 12.5.2.1 Projects aimed at promoting economic development to drive market 143
  - 12.5.3 SOUTH AFRICA 145
    - 12.5.3.1 Regional copper trade expansion to drive market 145
  - 12.5.4 REST OF MIDDLE EAST & AFRICA 146
- 12.6 SOUTH AMERICA 147
  - 12.6.1 BRAZIL 150
    - 12.6.1.1 Rapid industrial growth to drive market 150
  - 12.6.2 ARGENTINA 151
    - 12.6.2.1 Economic stabilization to drive market 151
  - 12.6.3 REST OF SOUTH AMERICA 152
- 13 COMPETITIVE LANDSCAPE 154
  - 13.1 INTRODUCTION 154
  - 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2025 154
  - 13.3 REVENUE ANALYSIS, 2022-2024 157
  - 13.4 MARKET SHARE ANALYSIS, 2024 157
  - 13.5 COMPANY VALUATION AND FINANCIAL METRICS 160
  - 13.6 PRODUCT COMPARISON 161
  - 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 161
    - 13.7.1 STARS 161
    - 13.7.2 EMERGING LEADERS 161
    - 13.7.3 PERVASIVE PLAYERS 162
    - 13.7.4 PARTICIPANTS 162
    - 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 163
      - 13.7.5.1 Company footprint 163
      - 13.7.5.2 Region footprint 163
      - 13.7.5.3 Material footprint 164
      - 13.7.5.4 Process technology footprint 165
      - 13.7.5.5 Application footprint 165
  - 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 166
    - 13.8.1 PROGRESSIVE COMPANIES 166
    - 13.8.2 RESPONSIVE COMPANIES 166
    - 13.8.3 DYNAMIC COMPANIES 166
    - 13.8.4 STARTING BLOCKS 166
    - 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 168
      - 13.8.5.1 Detailed list of key startups/SMEs 168
      - 13.8.5.2 Competitive benchmarking of startups/SMEs 169
  - 13.9 COMPETITIVE SCENARIO 170
    - 13.9.1 DEALS 170
    - 13.9.2 EXPANSIONS 171
- 14 COMPANY PROFILES 173
  - 14.1 KEY PLAYERS 173
    - 14.1.1 ASAHI KASEI CORPORATION 173

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.1.1	Business overview	173
14.1.1.2	Products offered	174
14.1.1.3	MnM view	175
14.1.1.3.1	Right to win	175
14.1.1.3.2	Strategic choices	175
14.1.1.3.3	Weaknesses and competitive threats	175
14.1.2	MANN+HUMMEL	176
14.1.2.1	Business overview	176
14.1.2.2	Products offered	177
14.1.2.3	MnM view	178
14.1.2.3.1	Right to win	178
14.1.2.3.2	Strategic choices	178
14.1.2.3.3	Weaknesses and competitive threats	178
14.1.3	SARTORIUS AG	179
14.1.3.1	Business overview	179
14.1.3.2	Products offered	180
14.1.3.3	MnM view	181
14.1.3.3.1	Right to win	181
14.1.3.3.2	Strategic choices	181
14.1.3.3.3	Weaknesses and competitive threats	181
14.1.4	MERCK KGAA	182
14.1.4.1	Business overview	182
14.1.4.2	Products offered	183
14.1.4.3	Recent developments	185
14.1.4.3.1	Expansions	185
14.1.4.4	MnM view	186
14.1.4.4.1	Right to win	186
14.1.4.4.2	Strategic choices	186
14.1.4.4.3	Weaknesses and competitive threats	186
14.1.5	SOLVENTUM	187
14.1.5.1	Business overview	187
14.1.5.2	Products offered	188
14.1.5.3	Recent developments	191
14.1.5.3.1	Deals	191
14.1.5.4	MnM view	192
14.1.5.4.1	Right to win	192
14.1.5.4.2	Strategic choices	192
14.1.5.4.3	Weaknesses and competitive threats	192
?		
14.1.6	CYTIVA (DANAHER CORPORATION)	193
14.1.6.1	Business overview	193
14.1.6.2	Products offered	194
14.1.6.3	Recent developments	196
14.1.6.3.1	Deals	196
14.1.6.3.2	Expansions	196
14.1.6.4	MnM view	197
14.1.7	W. L. GORE & ASSOCIATES, INC.	198

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.7.1	Business overview	198
14.1.7.2	Products offered	198
14.1.7.3	MnM view	199
14.1.8	KOVALUS SEPARATION SOLUTIONS	200
14.1.8.1	Business overview	200
14.1.8.2	Products offered	200
14.1.8.3	MnM view	201
14.1.9	COBETTER	202
14.1.9.1	Business overview	202
14.1.9.2	Products offered	202
14.1.9.3	MnM view	205
14.1.10	POREX	207
14.1.10.1	Business overview	207
14.1.10.2	Products offered	207
14.1.10.3	MnM view	209
14.2	OTHER PLAYERS	210
14.2.1	ADVANCED MICRODEVICES PVT. LTD.	210
14.2.2	AMERICAN MEMBRANE CORPORATION	211
14.2.3	AMS MEMTECH TECHNOLOGY (ZHEJIANG) CO., LTD	212
14.2.4	APPLIED MEMBRANE TECHNOLOGY, INC.	213
14.2.5	GRAVER TECHNOLOGIES	214
14.2.6	MEDICA SPA	215
14.2.7	MEMBRANE SOLUTIONS (NANTONG)	216
14.2.8	NX FILTRATION	217
14.2.9	OSMOTECH	218
14.2.10	PERMIONICS GROUP	219
14.2.11	REPLIGEN CORPORATION	220
14.2.12	SYNDER FILTRATION, INC.	221
14.2.13	THEWAY MEMBRANES	222
14.2.14	UNISOL MEMBRANE TECHNOLOGY	223
14.2.15	XINNA	224
	?	
15	RESEARCH METHODOLOGY	225
15.1	RESEARCH DATA	225
15.1.1	SECONDARY DATA	226
15.1.1.1	List of secondary sources	226
15.1.1.2	Key data from secondary sources	226
15.1.2	PRIMARY DATA	227
15.1.2.1	List of primary interview participants-demand and supply side	227
15.1.2.2	Key data from primary sources	227
15.1.2.3	Breakdown of primary interviews	228
15.1.2.4	Insights from industry experts	228
15.2	MARKET SIZE ESTIMATION	228
15.2.1	BOTTOM-UP APPROACH	229
15.2.2	TOP-DOWN APPROACH	229
15.3	FORECAST NUMBER CALCULATION	230
15.4	DATA TRIANGULATION	231

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.5	FACTOR ANALYSIS	232
15.6	RESEARCH ASSUMPTIONS	232
15.7	RESEARCH LIMITATIONS AND RISK ASSESSMENT	233
16	APPENDIX	234
16.1	DISCUSSION GUIDE	234
16.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	237
16.3	CUSTOMIZATION OPTIONS	239
16.4	RELATED REPORTS	239
16.5	AUTHOR DETAILS	240

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Medical Membranes Market by Material (PSU, PES, PVDF, PTFE, PP, PAN, PA, Modified Acrylics), Process Technology (Ultrafiltration, Microfiltration, Nanofiltration), Application (Pharmaceutical Filtration, Hemodialysis, IV Fusion & Sterile Filtration, Membrane Oxygenator), and Region - Global Forecast to 2030**

Market Report | 2025-11-28 | 241 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code\*

Country\*

Date

2026-03-03

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)